Biochem J 289(Pt 2): 331-334
Carrageenans inhibit growth-factor binding.
Abstract
Carrageenans, a family of polysulphated carbohydrates, inhibited binding of basic fibroblast growth factor (bFGF), transforming growth factor beta 1 (TGF beta 1) and platelet-derived growth factor (PDGF). iota-Carrageenan was the most potent bFGF antagonist (IC50 = 0.4 +/- 0.1 microgram/ml), kappa-carrageenan was the most potent PDGF antagonist (IC50 = 1.7 +/- 1.3 micrograms/ml) and lambda-carrageenan was the most potent TGF beta 1 antagonist (IC50 = 19 +/- 2 micrograms/ml). None of the carrageenans, at concentrations up to 200 micrograms/ml, inhibited binding of insulin-like growth factor 1 or transforming growth factor alpha. Carrageenans are selective growth-factor antagonists and have potential for the treatment of disorders associated with the over-production of certain growth factors.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (672K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bowen-Pope DF, Ross R. Methods for studying the platelet-derived growth factor receptor. Methods Enzymol. 1985;109:69–100. [PubMed] [Google Scholar]
- Coffey RJ, Jr, Leof EB, Shipley GD, Moses HL. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol. 1987 Jul;132(1):143–148. [PubMed] [Google Scholar]
- Coombe DR, Parish CR, Ramshaw IA, Snowden JM. Analysis of the inhibition of tumour metastasis by sulphated polysaccharides. Int J Cancer. 1987 Jan 15;39(1):82–88. [PubMed] [Google Scholar]
- Girond S, Crance JM, Van Cuyck-Gandre H, Renaudet J, Deloince R. Antiviral activity of carrageenan on hepatitis A virus replication in cell culture. Res Virol. 1991 Jul-Aug;142(4):261–270. [PubMed] [Google Scholar]
- Hoffman R, Cameron L. Characterization of a scintillation proximity assay to detect modulators of transforming growth factor alpha (TGF alpha) binding. Anal Biochem. 1992 May 15;203(1):70–75. [PubMed] [Google Scholar]
- Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem. 1985;29(3):265–273. [PubMed] [Google Scholar]
- Klagsbrun M. The affinity of fibroblast growth factors (FGFs) for heparin; FGF-heparan sulfate interactions in cells and extracellular matrix. Curr Opin Cell Biol. 1990 Oct;2(5):857–863. [PubMed] [Google Scholar]
- McCaffrey TA, Falcone DJ, Du B. Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1. J Cell Physiol. 1992 Aug;152(2):430–440. [PubMed] [Google Scholar]
- Moscatelli D. High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol. 1987 Apr;131(1):123–130. [PubMed] [Google Scholar]
- Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol. 1992 Jun;10(6):881–889. [PubMed] [Google Scholar]
- Pollak M, Richard M. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst. 1990 Aug 15;82(16):1349–1352. [PubMed] [Google Scholar]
- Tardieu M, Gamby C, Avramoglou T, Jozefonvicz J, Barritault D. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J Cell Physiol. 1992 Jan;150(1):194–203. [PubMed] [Google Scholar]
- van Boeckel CA, Grootenhuis PD, Haasnoot CA. Specificity in the recognition process between charged carbohydrates and proteins. Trends Pharmacol Sci. 1991 Jul;12(7):241–243. [PubMed] [Google Scholar]
- Vijayakumar RK, Muthukkaruppan VR. Immunoregulatory processes induced by carrageenan in BALB/C mice. Immunol Invest. 1990 Apr;19(2):163–183. [PubMed] [Google Scholar]
- Vlodavsky I, Fridman R, Sullivan R, Sasse J, Klagsbrun M. Aortic endothelial cells synthesize basic fibroblast growth factor which remains cell associated and platelet-derived growth factor-like protein which is secreted. J Cell Physiol. 1987 Jun;131(3):402–408. [PubMed] [Google Scholar]
- Wakefield LM. An assay for type-beta transforming growth factor receptor. Methods Enzymol. 1987;146:167–173. [PubMed] [Google Scholar]
- Wellstein A, Zugmaier G, Califano JA, 3rd, Kern F, Paik S, Lippman ME. Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst. 1991 May 15;83(10):716–720. [PubMed] [Google Scholar]
- Williams LT, Tremble PM, Lavin MF, Sunday ME. Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies. J Biol Chem. 1984 Apr 25;259(8):5287–5294. [PubMed] [Google Scholar]